Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation

NCT00586651 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00586651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00586651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Oral CEP-701 in Patients With Polycythemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
September 30, 2010
Enrollment
39 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocytosis, polycythemia vera